The major goal of the Dominantly Inherited Alzheimer Network Neuropathology Core (DIAN-NPC) is to provide a neuropathological diagnosis on all participants in DIAN and family members who come to autopsy, to exchange data with the DIAN Coordinating Center, and to provide diagnostic reports and tissues to collaborating sites. The DIAN-NPC provides the
Although there have been tremendous advances in the development of biomarkers of Alzheimers disease, there remains no reliable method for showing the earliest pathological changes in the brain or the presence of additional pathology which may contribute to the progression and symptoms of the disease. The Neuropathology Core of DIAN is essential to provide a neuropathological diagnosis on all participants and family members who come to autopsy - it is the gold standard against which all biomarker and clinical assessments are judged. The importance of the Neuropathology Core is demonstrated by the observation that in DIAN participants there often is additional Lewy body disease that was not detected by any biomarker, clinical or other assessment and likely contributes to the rate and nature of the cognitive and motor impairment in vulnerable individuals.
|Ringman, John M; Goate, Alison; Masters, Colin L et al. (2014) Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. Curr Neurol Neurosci Rep 14:499|
|Thomas, Jewell B; Brier, Matthew R; Bateman, Randall J et al. (2014) Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol 71:1111-22|
|Xiong, Chengjie; Weng, Hua; Bennett, David A et al. (2014) Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease. Neuroepidemiology 43:131-9|
|Dobrowolska, Justyna A; Kasten, Tom; Huang, Yafei et al. (2014) Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One 9:e89998|